Noninvasive Prostate Cancer Treatment Data is Maturing & Promising
June 21, 2013
By Robert M. Meier, MD
Radiation Oncology Medical Director, Swedish Radiosurgery Center
Many of my patients are men seeking prostate cancer treatment they can undergo while continuing work and maintaining active lifestyles. Equally important is the cancer-free survival rate and long-term side effect profile. For over seven years we have been treating men with organ-confined prostate cancer using the CyberKnife® stereotactic radiosurgery system. This sophisticated radiation delivery system uses a robotic arm to deliver precise treatment doses to the prostate in only 5 sessions so the men can keep up their normal routine while combating their disease.
The data supporting this treatment option continues to grow and a recent study following men for 6 years reports patients had excellent biochemical control rates (based on PSA measurements) and minimal bowel and urinary side effects. For patients who were potent prior to treatment, 75% said they remained potent following CyberKnife therapy. These results are very similar to the multicenter study I led where we reported the 5 year data in October. We are continuing to follow these patients and the results are very promising with a cancer-free survival rate of 99%. Based on the collective research, the American Society for Radiation Oncology (ASTRO) has stated “It is ASTRO’s opinion that data supporting the use of SBRT (Stereotactic Body Radiation Therapy) for prostate cancer have matured to a point where SBRT could be considered an appropriate alternative for select patients with low to intermediate risk disease.”
For many men, this form of targeted treatment is an excellent option to consider. Click here to learn more about radiosurgery options for prostate cancer.